HMA - Heads of Medicines Agencies
  • RSS
  • Sitemap
  • Contact
  • About HMA
  • Human Medicines
  • Veterinary Medicines
  • You are here:
  • Home
  • >About HMA
  • >Transparency
  • >Guideline for transparency
  • >Archive · Guideline and recommendations for transparency
  • Vision and mission
  • Structure
  • Working Groups
  • National Contacts
  • COVID-19
  • Combination products
  • Transparency
    • Guideline for transparency
      • Archive · Guideline and recommendations for transparency
  • Meetings
  • Medicines Approval system
  • Publications and reports
  • Recently Published
  • Newsletters

 

Guideline and recommendations for transparency


Recommendations for transparency

Release of information concerning new applications for marketing authorisation for medicinal products before and after the decision is made ​​MT | pdf
Requests for access to PSURs (Periodic Safety Update Reports) (November 2009) | pdf
Agenda for product related issues (November 2008) | pdf

For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.

  • Useful Links
  • Privacy Policy
  • Credits & Disclaimer
  • Contact
© Heads of Medicines Agencies - https://www.hma.eu/about-hma/transparency/guideline-for-transparency/archive-guideline-and-recommendations-for-transparency.html